AWAKN Life Sciences Inc. (“AWAKN”), has signed a binding funding settlement to accumulate a controlling curiosity in Mandala Therapy Limited, the UK based mostly psychedelic medical observe run by acclaimed creator, researcher and advisor psychiatrist, Dr. Ben Sessa.

Dr. Sessa will develop into AWAKN’s Chief Medical Officer and can open the UK’s first psychedelic-assisted psychotherapy clinic over the coming months. Under his management, AWAKN intends to supervise a revolutionary shift in the therapy method for psychological well being issues, all backed by scientific proof that triggered the FDA to grant breakthrough-therapy standing for MDMA and psilocybin.

As a part of the settlement, Dr. Sessa can be constructing coaching pathways that can open entry for psychiatrists and psychologists throughout the nation. AWAKN expects the UK to proceed to progress in direction of medicalising psychedelics, at present enterprise trials for MDMA and psilocybin whereas political reform is being led by Crispin Blunt MP and the Conservative Drug Reform Group.

Speaking of the acquisition, Dr. Sessa stated, “Enough of the incessant belief that mental health disorders cannot be cured, this is the legacy of the ill-informed. Psychedelics have the potential to heal when used correctly and with psychotherapy pathways built for purpose. We are progressive thinkers at AWAKN Life Sciences and see the need for clinics that are experts in the use of psychedelic medicine under safe, efficacious and scientifically validated frameworks. We are building the centre of excellence for the UK.”

Commenting on the entry into the UK, AWAKN CEO Anthony Tennyson stated, “We see the early mover advantage in the UK market with patients already using ketamine as part of their treatment plans. Now is the time to build the UK’s first psychedelic clinic to heal the growing tide of the mentally ill, and there is no-one better to lead the renaissance than Dr. Sessa. He has dedicated his professional career to psychedelic medicine, and we are honoured to have him leading our medical team.”

The transaction by AWAKN marks the first of its sort by a Canadian firm in the UK and follows a interval of big progress of capital being invested in the psychedelic market throughout North America and Europe. The completion of the acquisition stays topic to sure closing circumstances.

About AWAKN Life Sciences Inc.

AWAKN Life Sciences Inc. supplies evidence-based Psychedelic Assisted Psychotherapy options to heal psychological well being circumstances. Our focus is making certain optimum affected person security, whereas delivering efficacy by transformative affected person care, in conjunction with scientifically validating long-term psychological well being.

About Dr. Ben Sessa

Dr. Sessa’s joint pursuits in psychotherapy, pharmacology and trauma have led him in direction of researching the topic of drug-assisted psychotherapy utilizing psychedelic adjuncts. He is the creator of psychedelic medical exploration books together with The Psychedelic Renaissance (2012) and To Fathom Hell or Soar Angelic (2015), whereas he’s at present conducting analysis with Imperial College London on the position for MDMA-assisted remedy for the therapy of PTSD and alcohol dependence syndrome. Dr. Sessa is outspoken on lobbying for change in the present system by which medicine are categorised in the UK, believing a extra progressive coverage of regulation would cut back the harms of leisure drug use. He is a co-founder and director of the UK’s Breaking Convention convention.

More Information

Anthony Tennyson | CEO
anthony@awaknlifesciences.com

Dr. Ben Sessa | CMO
ben@awaknlifesciences.com

awaknlifesciences.com

Source:  https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/psychedelic-medical-start-up-awakn-life-sciences-enters-the-uk-market-with-dr-ben-sessa/

Source link